T-Cell Directed Therapy in MS

Program Objectives

T Cells and B Cells in MS

T-Cell Directed Therapies: Alemtuzumab and Cladribine

T-Cell Directed Therapies: Daclizumab

T-Cell Directed Therapies: Fingolimod

T-Cell Directed Therapies: Natalizumab

T-Cell Directed Therapies: DMF

Evolution of Outcome Measures in MS

Evolution of NEDA in MS[a]

Practical Considerations in Implementing NEDA in Clinical Practice

NEDA as an Endpoint: Single-Center Data

NEDA as an Endpoint: Single-Center Data (cont)

NEDA as an Endpoint: Clinical Trial Data

Achieving NEDA With Cladribine: CLARITY

Achieving NEDA With Alemtuzumab: CARE-MS

Achieving NEDA With Daclizumab: DECIDE

Achieving DAF With Natalizumab: AFFIRM

Achieving NEDA With DMF: DEFINE/CONFIRM

Achieving NEDA-3 and NEDA-4 With Fingolimod: TRANSFORMS

Challenge of Implementing NEDA-4 in Clinical Practice

Achieving NEDA With Fingolimod: Real-World Data

Benefit/Risk Assessment in Targeting NEDA

Reversible Lymphocyte Redistribution With Fingolimod

Lymphopenia in Patients Treated With DMF

Lymphopenia in Patients Treated With Alemtuzumab or Cladribine

Setting Lymphocyte Count Thresholds in Clinical Practice

Treating to NEDA in Clinical Practice

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)